Highlights Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

End-of-day quote Korea S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
112,700 ^KRW	+1.17%		+1.81%	-3.51%

04-24	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT
04-12	AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia	02-15	MT
Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., Ltd. Announces Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S	12-11	CI
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy	11-06	CI
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema	25/09/23	CI
Hyphens Pharma International Limited Announces Successful Registration in Malaysia	30/08/23	CI
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Daewoong Pharmaceutical Enters into License and Distribution Agreement with Cooper Pharma	24/07/23	CI
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	20/07/23	CI
Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet	19/07/23	CI
Daewoong Pharmaceutical Regaining Rights to Fexuprazan in the United States and Canada Upon Termination of License Agreement with Neurogastrx	05/06/23	CI
Avacta Group Plc acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd.	04/06/23	CI
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023	19/05/23	CI
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Daewoong pharmaceutical Co.,Ltd's Envlo to Enter the Global Market in Full Swing with Filing for Product License in Three Asean Countries	22/03/23	CI
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	08/03/23	CI
M8 Pharmaceuticals and Daewoong Pharmaceutical Strengthens Strategic Partnership by Signing an Exclusive Licensing Agreement for Envlo (Enavoglifozin) for Brazil and Mexico	28/02/23	CI
Daewoong Pharmaceutical Begins the First Administration of Bersiporocin	06/02/23	CI
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea	31/01/23	CI
Daewoong Pharmaceutical Co.,Ltd Submits NDA for Its Global New Drug Fexuclue in 11 Countries, Only 1 Year After Approval in Korea	26/01/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

Highlights

Filters